Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792892 | 1.00 | PARP1 (0.56) | PARP1CYP1A2HPGDKDM4EALDH1A1 | |
| SCHEMBL31439279 | 0.78 | PARP1 (0.38) | PARP1CYP1A2 | |
| SCHEMBL16695658 | 0.77 | KDM4D (0.48) | PARP1CYP1A2HPGDCYP2C9 | |
| SCHEMBL16695670 | 0.75 | PARP1 (0.55) | PARP1CYP1A2HPGDKDM4EALDH1A1 | |
| SCHEMBL30773073 | 0.75 | PARP1 (0.55) | PARP1CYP1A2HPGDKDM4EALDH1A1 | |
| SCHEMBL2274845 | 0.74 | ADORA3 (0.37) | PARP1CYP1A2HPGDALDH1A1 | |
| SCHEMBL7135462 | 0.72 | ALDH1A1 (0.51) | PARP1CYP1A2HPGDKDM4EALDH1A1 | |
| SCHEMBL29792766 | 0.72 | PARP1 (1.00) | PARP1CYP1A2RAB9A | |
| SCHEMBL16695791 | 0.72 | PARP1 (1.00) | PARP1CYP1A2RAB9A | |
| SCHEMBL9598688 | 0.71 | PARP1 (0.51) | PARP1CYP1A2HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-31 | — | — | US | claimed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | claimed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | claimed |
| EP-2861597-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2015-04-22 | — | — | EP | claimed |
| WO-2013174822-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2013-11-28 | — | — | WO | claimed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| CN-117561258-A | Novel substituted tricyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-31 | — | — | US | disclosed |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11045562-B2 | Radiolabelled mGluR2/3 PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-29 | — | — | US | disclosed |
| EP-2598491-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | Cadila Healthcare Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137695-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2013-05-30 | — | — | US | disclosed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2012014221-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045562-B2 | Radiolabelled mGluR2/3 PET ligands | GRM3, GRM2, GRM1 | PARP1 4785/4885CYP1A2 3179/4885HPGD 2554/4885 |
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 782/4885HPGD 392/4885 |
| US-20130137695-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS | PARP1, PARP2, PARP11 | PARP1 1/4885CYP1A2 1638/4885HPGD 1406/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | PARP1 4108/4885CYP1A2 2683/4885HPGD 2718/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 782/4885HPGD 392/4885 |
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | PARP1, PARP3, PARP11 | PARP1 1/4885CYP1A2 4487/4885HPGD 2766/4885 |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | PARP1 303/4885CYP1A2 1303/4885HPGD 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.